Ironwood Pharmaceuticals (NASDAQ:IRWD) Sets New 12-Month Low – Should You Sell?

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)’s stock price hit a new 52-week low during trading on Friday . The company traded as low as $3.06 and last traded at $3.18, with a volume of 225854 shares changing hands. The stock had previously closed at $3.34.

Analyst Ratings Changes

IRWD has been the subject of several recent analyst reports. Leerink Partnrs raised shares of Ironwood Pharmaceuticals to a “hold” rating in a research note on Monday, September 9th. Leerink Partners initiated coverage on shares of Ironwood Pharmaceuticals in a research note on Monday, September 9th. They issued a “market perform” rating and a $5.00 price objective for the company. Finally, StockNews.com downgraded Ironwood Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Tuesday, November 12th. Three investment analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $10.40.

Ironwood Pharmaceuticals Trading Up 2.7 %

The company’s 50-day moving average is $4.06 and its 200 day moving average is $5.08. The stock has a market capitalization of $548.90 million, a PE ratio of -114.33 and a beta of 0.41.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last posted its quarterly earnings results on Thursday, November 7th. The biotechnology company reported $0.02 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.07). Ironwood Pharmaceuticals had a negative return on equity of 0.96% and a negative net margin of 0.65%. The business had revenue of $91.60 million for the quarter, compared to analysts’ expectations of $91.22 million. During the same period in the prior year, the business posted $0.12 earnings per share. The business’s quarterly revenue was down 19.4% compared to the same quarter last year. Sell-side analysts forecast that Ironwood Pharmaceuticals, Inc. will post 0.08 EPS for the current fiscal year.

Insider Buying and Selling at Ironwood Pharmaceuticals

In other Ironwood Pharmaceuticals news, CFO Sravan Kumar Emany sold 11,001 shares of the business’s stock in a transaction that occurred on Monday, November 18th. The stock was sold at an average price of $4.08, for a total transaction of $44,884.08. Following the completion of the sale, the chief financial officer now directly owns 309,572 shares in the company, valued at approximately $1,263,053.76. The trade was a 3.43 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 12.90% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. CWM LLC grew its holdings in shares of Ironwood Pharmaceuticals by 55.1% during the 2nd quarter. CWM LLC now owns 6,600 shares of the biotechnology company’s stock worth $43,000 after purchasing an additional 2,345 shares during the period. KBC Group NV lifted its position in shares of Ironwood Pharmaceuticals by 59.3% during the third quarter. KBC Group NV now owns 8,593 shares of the biotechnology company’s stock worth $35,000 after purchasing an additional 3,198 shares in the last quarter. First Dallas Securities Inc. acquired a new position in shares of Ironwood Pharmaceuticals in the second quarter valued at approximately $73,000. Diversified Trust Co acquired a new position in shares of Ironwood Pharmaceuticals in the third quarter worth $52,000. Finally, Wolverine Trading LLC acquired a new stake in shares of Ironwood Pharmaceuticals in the third quarter valued at $51,000.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.